Last edition
News about "lung cancer treatment"
Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China
Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.
Lung Cancer Treatment | 15/09/2026 | By News Bureau
Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial
Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer Treatment | 02/07/2026 | By News Bureau | 158
GSK Enters Agreement to Acquire Nuvalent
GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.
Lung Cancer Treatment | 10/06/2026 | By News Bureau | 307
US FDA Grants Priority Review to HYRNUO for HER2-Mutated NSCLC
The US FDA has granted Priority Review (PR) to HYRNUO (sevabertinib) as a first-line treatment for HER2-mutated Non-Small Cell Lung Cancer (NSCLC), based on phase 1/2 SOHO-01 trial data.
Lung Cancer Treatment | 21/05/2026 | By News Bureau | 151
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
Lung Cancer Treatment | 07/05/2026 | By News Bureau | 165
Eisai and Nuvation Bio Secure EMA Validation for Taletrectinib in Lung Cancer
EU regulator begins review of next-generation targeted therapy for advanced ROS1-positive non-small cell lung cancer.
Lung Cancer Treatment | 30/03/2026 | By News Bureau | 335
Bridge Biotherapeutics and HitGen to Advance Novel Cancer Therapeutics Program
Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets.
Lung Cancer Treatment | 23/08/2024 | By Aishwarya | 618
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy